Jiangsu Hengrui Pharmaceuticals (600276.SH): RSS0393 ointment approved for clinical trials.

Jiangsu Hengrui Pharmaceuticals (600276.SH) has announced that its subsidiary Ruishi Biopharmaceutical Co., Ltd. has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials on the RSS0393 ointment. The ointment, developed by the company, contains a small molecule inhibitor of PDE4 which can relieve tissue damage and inflammation by inhibiting the activity of PDE4 in various cells. The clinical trials will commence soon.